AIM
ADMA icon

Aigen Investment Management’s ADMA Biologics ADMA Stock Holding History

Aigen Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,212
Closed -$101K – 522
2026
Q1 		$101K Buy
+11,212
New +$177K 0.03% 466
2025
Q1 		– Sell
-29,513
Closed -$506K – 735
2024
Q4 		$506K Buy
29,513
+370
+1% +$6.96K 0.09% 327
2024
Q3 		$583K Buy
+29,143
New +$453K 0.11% 275
2023
Q4 		– Sell
-39,052
Closed -$140K – 763
2023
Q3 		$140K Buy
+39,052
New +$150K 0.03% 717
2020
Q3 		– Sell
-29,691
Closed -$87K – 833
2020
Q2 		$87K Buy
+29,691
New +$85.3K 0.01% 766

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aigen Investment Management's ADMA Position: Q2 2026 in Review

Aigen Investment Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 11,212 shares — an estimated $101K sold.

Aigen Investment Management first reported a position in ADMA in Q2 2020 and held it in 5 quarters. The position peaked at $583K in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Aigen Investment Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Aigen Investment Management sold 11,212 ADMA Biologics shares in Q2 2026, an estimated $101K.
  • Aigen Investment Management first reported a position in ADMA Biologics in Q2 2020 and held it in 5 quarters.
  • Aigen Investment Management's ADMA Biologics position peaked at $583K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.